Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy

NCT01110720 is registered in ClinicalTrials.gov with Allon Therapeutics as lead sponsor.

NCT NCT01110720
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01110720 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 2/3, Randomized, Double-Blind, Placebo-Controlled, Study to Evaluate the Safety and Efficacy of Davunetide for the Treatment of Progressive Supranuclear Palsy
Lead sponsor
Allon Therapeutics
Phase
Phase 2/3
Overall status
Completed
Start date
October 31, 2010
Completion date
December 31, 2012
Enrollment
313 (actual)
Sites
48

Conditions

As the registry lists them; a condition with its own page is linked.

progressive supranuclear palsy